Meeting
2022 ASCO Annual Meeting
Differences in clinician and patient assessment of baseline neuropathy in patients receiving taxane-based chemotherapy enrolled to SWOG S1714 (NCT# 03939481).
Authors
Meghna S. Trivedi
Columbia University Irving Medical Center, New York, NY
Meghna S. Trivedi , Joseph M. Unger , Dawn L. Hershman , Amy Darke , Daniel Louis Hertz , Thomas Brannagan , Stephanie Smith , William Johnson Irvin Jr., Amanda Redden Hathaway , Amy C. Vander Woude , Vinay K. Gudena , Norah Lynn Henry , Michael Jordan Fisch
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Symptoms and Survivorship
Track
Symptom Science and Palliative Care
Sub Track
Late and Long-Term Adverse Effects
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 12024)
DOI
10.1200/JCO.2022.40.16_suppl.12024
Abstract #
12024
Poster Bd #
270
Abstract Disclosures
Similar Posters
Poster
2015 Breast Cancer Symposium
Predictors of chemotherapy-induced peripheral neuropathy among breast cancer patients treated with taxanes.
First Author: Nellowe Candelario
Poster
2016 ASCO Annual Meeting
Longitudinal changes in patient-reported symptoms and physical function during taxane-based chemotherapy in breast cancer patients.
First Author: Scott M. Monfort
Poster
2013 Breast Cancer Symposium
Elevated extracellular fluid in the "at risk" arm from taxane-based chemotherapies in women treated for early breast cancer.
First Author: Sharon Lynn Kilbreath
Poster
2023 ASCO Annual Meeting
Impact of exercise on chemotherapy-induced peripheral neuropathy (CIPN) in survivors with post-treatment primary breast cancer.
First Author: Kirin Saint